At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 238 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Imatinib for Leukemia. Completed, enrolled 238 participants across 72 sites in 24 countries.
Detailed Summary
This study assesses the long-term safety and tolerability of dasatinib administered to patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia and experienced clinical benefit from treatment with dasatinib or imatinib in previous protocols.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesArgentina, Australia, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Norway, Peru, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedSep 2009
Primary CompletionDec 2014
TodayJul 2026
First PostedSep 23, 2009
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 16.8 years ago
Interventions
Dasatinibdrug
Dasatinib was supplied as 20- and 50-mg tablets.
Imatinibdrug
Imatinib was supplied as 100- and 400-mg tablets.